Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Studie av effektivitet og sikkerhet av LNP023 hos deltakere med aktiv lupus nefritis klasse III-IV, +/- V

9. oktober 2026 oppdatert av: Novartis Pharmaceuticals

En adaptiv, randomisert, dobbeltblind, doseutforskning, parallell gruppe, placebokontrollert, multisenter fase 2-forsøk for å evaluere effektiviteten, sikkerheten og tolerabiliteten til LNP023 i kombinasjon med standardbehandling med og uten orale kortikosteroider hos pasienter med aktiv lupus Nefritt klasse III-IV, +/- V

The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.

Studieoversikt

Detaljert beskrivelse

The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.

Studietype

Intervensjonell

Registrering (Faktiske)

81

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Santa Fe, Argentina, S3000EPV
        • Novartis Investigative Site
      • Salvador, Brasil, 40323-010
        • Novartis Investigative Site
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasil, 40150-150
        • Novartis Investigative Site
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brasil, 30150-221
        • Novartis Investigative Site
      • Juiz de Fora, Minas Gerais, Brasil, 36010-570
        • Novartis Investigative Site
    • São Paulo
      • Barretos, São Paulo, Brasil, 14784-400
        • Novartis Investigative Site
      • São Paulo, São Paulo, Brasil, 05403-000
        • Novartis Investigative Site
      • São Paulo, São Paulo, Brasil, 04038-002
        • Novartis Investigative Site
      • São Paulo, São Paulo, Brasil, 01308-050
        • Novartis Investigative Site
      • Montería, Colombia, 230004
        • Novartis Investigative Site
    • Atlántico
      • Barranquilla, Atlántico, Colombia, 080020
        • Novartis Investigative Site
    • Cundinamarca
      • Bogota, Cundinamarca, Colombia, 111411
        • Novartis Investigative Site
    • Santander Department
      • Bucaramanga, Santander Department, Colombia, 680003
        • Novartis Investigative Site
      • Quezon, Filippinene, 1102
        • Novartis Investigative Site
    • National Capital Region
      • Makati City, National Capital Region, Filippinene, 1218
        • Novartis Investigative Site
    • California
      • Los Angeles, California, Forente stater, 90095
        • Ronald Reagan UCLA Medical Center
      • San Bernardino, California, Forente stater, 92408
        • Loma Linda University
      • Sylmar, California, Forente stater, 91342
        • Olive View UCLA Medical Center
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • University of Colorado Denver
    • Florida
      • Hollywood, Florida, Forente stater, 33021
        • Royal Research Corp
      • Orlando, Florida, Forente stater, 32806
        • Nephrology Associates Of Central FL
      • Riverview, Florida, Forente stater, 33578
        • Florida Kidney Physicians
    • Illinois
      • Hinsdale, Illinois, Forente stater, 60521
        • Nep Assoc of Northern Illinois
    • Kansas
      • Wichita, Kansas, Forente stater, 67214
        • Wichita Community Clcl Onco Program
    • Louisiana
      • New Orleans, Louisiana, Forente stater, 70121
        • Ochsner Health System
    • Maryland
      • Baltimore, Maryland, Forente stater, 21287
        • Johns Hopkins Hospital
    • New York
      • East Setauket, New York, Forente stater, 11733
        • Stony Brook Internists PC
    • Ohio
      • Cleveland, Ohio, Forente stater, 44195
        • Cleveland Clinic Foundation
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19140
        • Temple University
    • Texas
      • Dallas, Texas, Forente stater, 75204
        • Dallas Nephrology Associates
      • Houston, Texas, Forente stater, 77054
        • Prolato Clinical Research Center
      • Marseille, Frankrike, 13005
        • Novartis Investigative Site
      • Nantes, Frankrike, 44093
        • Novartis Investigative Site
    • Hong Kong
      • Hong Kong, Hong Kong, Hong Kong, 999077
        • Novartis Investigative Site
    • Kerala
      • Kozhikode, Kerala, India, 673008
        • Novartis Investigative Site
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, India, 110029
        • Novartis Investigative Site
    • Telangana
      • Hyderabad, Telangana, India, 500082
        • Novartis Investigative Site
    • Uttar Pradesh
      • Lucknow, Uttar Pradesh, India, 226014
        • Novartis Investigative Site
      • Beijing, Kina, 100034
        • Novartis Investigative Site
      • Shenzhen, Kina, 518036
        • Novartis Investigative Site
    • Guangxi
      • Nanning, Guangxi, Kina, 530022
        • Novartis Investigative Site
    • Hubei
      • Wuhan, Hubei, Kina, 430022
        • Novartis Investigative Site
    • Liaoning
      • Shenyang, Liaoning, Kina, 110004
        • Novartis Investigative Site
    • Ningxia
      • Yinchuan, Ningxia, Kina, 750004
        • Novartis Investigative Site
      • Selangor Darul Ehsan, Malaysia, 68100
        • Novartis Investigative Site
    • Pahang
      • Kuantan, Pahang, Malaysia, 25100
        • Novartis Investigative Site
    • Perak
      • Taiping, Perak, Malaysia, 34000
        • Novartis Investigative Site
      • Aguascalientes, Mexico, 20230
        • Novartis Investigative Site
      • Veracruz, Mexico, 91900
        • Novartis Investigative Site
    • Tamaulipas
      • Tampico, Tamaulipas, Mexico, 89440
        • Novartis Investigative Site
    • Yucatán
      • Mérida, Yucatán, Mexico, 97070
        • Novartis Investigative Site
      • Carnaxide, Portugal, 2799-523
        • Novartis Investigative Site
      • Coimbra, Portugal, 3004-561
        • Novartis Investigative Site
      • Lisbon, Portugal, 1649-035
        • Novartis Investigative Site
      • Vila Nova de Gaia, Portugal, 4434-502
        • Novartis Investigative Site
      • San Juan, Puerto Rico, 00927
        • FDI Clinical Research
    • Singapore
      • Singapore, Singapore, Singapore, 308433
        • Novartis Investigative Site
      • Barcelona, Spania, 08036
        • Novartis Investigative Site
      • Ciudad Real, Spania, 13005
        • Novartis Investigative Site
      • Madrid, Spania, 28034
        • Novartis Investigative Site
      • Madrid, Spania, 28040
        • Novartis Investigative Site
      • Seville, Spania, 41009
        • Novartis Investigative Site
      • Cambridge, Storbritannia, CB2 0QQ
        • Novartis Investigative Site
    • Fatih
      • Istanbul, Fatih, Tyrkia (Türkiye), 34093
        • Novartis Investigative Site
    • Melikgazi
      • Kayseri, Melikgazi, Tyrkia (Türkiye), 38039
        • Novartis Investigative Site
    • Nilufer
      • Bursa, Nilufer, Tyrkia (Türkiye), 16059
        • Novartis Investigative Site
    • Yenimahalle
      • Ankara, Yenimahalle, Tyrkia (Türkiye), 06500
        • Novartis Investigative Site
    • Yenisehir
      • Mersin, Yenisehir, Tyrkia (Türkiye), 33110
        • Novartis Investigative Site
      • Mainz, Tyskland, 55131
        • Novartis Investigative Site
    • Lower Saxony
      • Braunschweig, Lower Saxony, Tyskland, 38126
        • Novartis Investigative Site
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Tyskland, 51109
        • Novartis Investigative Site
      • Budapest, Ungarn, 1083
        • Novartis Investigative Site
      • Szeged, Ungarn, 6725
        • Novartis Investigative Site
    • Hajdu Bihar Megye
      • Debrecen, Hajdu Bihar Megye, Ungarn, 4032
        • Novartis Investigative Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 100 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

Unequivocally positive ANA test result and/or a positive anti dsDNA at screening Active biopsy-proven lupus nephritis within 3 months of screening demonstrating Class III or IV lupus nephritis with or without co-existing features of Class V lupus nephritis.

Documentation of active renal disease at the time of screening necessitating the commencement of therapy with corticosteroids in combination with MMF/MPS.

eGFR ≥ 30 ml/min/1.73 m2 Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infections Vaccination against Haemophilus influenzae infection Supportive care including stable dose regimen of anti-malarials (e.g. hydroxychloroquine) unless contraindicated, ACEi or ARB at either locally approved maximal daily dose or the maximally tolerated dose (per investigators' judgement) at screening, as per the local clinical practice. Doses should remain stable throughout the study.

First presentation or flare of lupus nephritis.

Exclusion Criteria:

Induction treatment with cyclophosphamide within 3 months of planned treatment for this study; treatment with calcineurin inhibitors within the previous 3 months prior to randomization.

Presence of rapidly progressive glomerulonephritis (RPGN) as defined by 50% decline in eGFR within 3 months prior to screening.

Renal biopsy presenting with interstitial fibrosis/tubular atrophy (IF/TA) or glomerulosclerosis of more than 50%, or which in the opinion of the investigator is such that it precludes likely response to immunosuppressive therapy.

Participants being treated with systemic corticosteroids (>5 mg/day prednisone or equivalent) for indications other than SLE or LN e.g. acute asthma, inflammatory bowel disease.

Participants being treated with systemic corticosteroids for SLE or LN will be excluded if they have taken more than an average of 15 mg/day prednisone (or equivalent) in the previous 4 weeks and more than an average of 30 mg/day in the previous 1 week Receipt of more than a total dose of 1000 mg equivalent i.v. pulse methylprednisolone (cumulative dose) within 2 weeks prior to enrollment (and at enrollment)

Other protocol-defined inclusion/exclusion criteria may apply

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Iptacopan + standard of care (part 1)

Iptacopan + standard of care

Taken for 52 Weeks

Andre navn:
  • LNP023
Placebo komparator: Placebo matching iptacopan + standard of care (part 1)

Placebo matching iptacopan standard of care

Taken for 52 Weeks

Aktiv komparator: Iptacopan + standard of care (part 2)

Iptacopan + standard of care

Taken for 52 Weeks

Andre navn:
  • LNP023
Aktiv komparator: Iptacopan + placebo (part 2)

Iptacopan + placebo standard of care

Taken for 52 Weeks

Andre navn:
  • LNP023 og placebo
Aktiv komparator: Placebo matching iptacopan + standard of care (part 2)

Placebo matching iptacopan + standard of care

Taken for 52 Weeks

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Part 1 and 2: Proportion of patients achieving Complete Renal Response (CRR) at week 24 in the absence of renal flares
Tidsramme: Baseline and week 24

Part 1: To evaluate the proportion of patients achieving complete renal response with iptacopan treatment "A" plus standard of care, compared to treatment alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "B" plus standard of care, compared to treatment "D" alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "C" plus standard of care, compared to treatment "D" alone

Complete Renal Response is defined as meeting the following criteria: estimated glomerular filtration rate (eGFR) ≥ 90 mL/min/1.73 m2 or no less than 85% of baseline value, and 24h urine protein-to-creatinine ratio (UPCR) ≤ 0.5 g/g.

Baseline and week 24

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Parts 1 and 2: Proportion of patients achieving CRR or PRR in the absence of renal flares
Tidsramme: Baseline, week 24, week 52

Proportion of patients achieving complete renal response or partial renal response

Baseline, week 24, week 52
Proportion of patients achieving ≥25% UPCR reduction in the absence of renal flares compared to baseline at week 24
Tidsramme: Baseline, week 24 week 52

Frequency of renal flares between weeks 24 and 52

Baseline, week 24 week 52
Log-transformed ratio to baseline of 24h UPCR at week 24
Tidsramme: Baseline week 24

Dose exposure response for reduction in proteinurea. (each 24h urine protein-to-creatinine ratio value will based on two 24 urine collections sampled within 10 days before the respective study visit)

Baseline week 24
Change from baseline FACIT-Fatigue Score
Tidsramme: Weeks 24 and 52

Measure fatigue in patients

Weeks 24 and 52
Change from baseline in SLEDAI-2K score at weeks 24 and 52
Tidsramme: Weeks 24 and 52

Measure disease activity in SLE

Weeks 24 and 52
Change from baseline in BILAG-2004 score at weeks 24 and 52
Tidsramme: Weeks 24 and 52

Measure disease activity

Weeks 24 and 52
Time-to-Complete Renal Response (CRR) based on first morning void(FMV) urine samples
Tidsramme: Week 24 and Week 52

Measurement of time to complete renal response based on urine samples

Week 24 and Week 52

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

10. august 2022

Primær fullføring (Faktiske)

19. mars 2026

Studiet fullført (Faktiske)

1. oktober 2026

Datoer for studieregistrering

Først innsendt

24. februar 2022

Først innsendt som oppfylte QC-kriteriene

24. februar 2022

Først lagt ut (Faktiske)

7. mars 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

15. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere